ΒΆ Prostaglandins
A family of 20-carbon lipid mediators derived from arachidonic acid (and other fatty acids) through Cyclooxygenase (COX) enzyme activity. Include multiple subtypes (PGE2, PGD2, PGF2Ξ±, PGI2/prostacyclin, TXA2/thromboxane) with context-dependent and often opposing roles in inflammation, pain, fever, vascular tone, gastric protection, and tissue Homeostasis. Prostaglandins act locally through G-protein coupled receptors and are rapidly metabolized, making them short-lived autocrine/paracrine signals.
The Fire Department with Multiple Divisions
Imagine a fire station that responds to emergencies, but instead of one unified response team, it has five specialized divisions (PGE2, PGD2, PGF2Ξ±, PGI2, TXA2) β all built from the same raw material (arachidonic acid), all dispatched by the same alarm system (COX enzymes), but each with completely different jobs.
PGE2 is the paradoxical division: it initially rushes to the fire scene and increases alarm sensitivity (pain, fever, inflammation), but then switches roles mid-emergency and starts organizing cleanup crews and telling everyone else to calm down (anti-inflammatory, promotes resolution). PGI2 is the traffic controller β it keeps blood vessels wide open and prevents platelet roadblocks. TXA2 is the opposite β it closes lanes and stacks platelet sandbags to stop bleeding. PGF2Ξ± controls muscle contractions in the uterus and eyes. PGD2 handles allergic responses and sleep regulation.
The critical point: when you take an NSAID, you're not selectively shutting down one division β you're disabling the entire fire station. You lose the alarm system (no pain signal), but you also lose gastric protection (ulcers), kidney regulation (fluid retention), and the cleanup coordination (delayed resolution). This is why blocking all prostaglandins reduces pain and inflammation but creates a cascade of side effects β you've removed both the problem AND the solution mechanisms.
graph TD
A[Cell membrane phospholipids] -->|Phospholipase A2| B["Arachidonic acid 20:4 n-6"]
B -->|COX-1 constitutive| C[PGH2]
B -->|COX-2 inducible| C
C -->|PGE synthase| D[PGE2]
C -->|PGD synthase| E[PGD2]
C -->|PGF synthase| F["PGF2Ξ±"]
C -->|PGI synthase| G[PGI2 prostacyclin]
C -->|Thromboxane synthase| H[TXA2 thromboxane]
D -->|EP1-EP4 receptors| I[Context-dependent effects]
E -->|DP1-DP2 receptors| J[Allergic & sleep regulation]
F -->|FP receptor| K[Smooth muscle contraction]
G -->|IP receptor| L[Vasodilation, anti-thrombotic]
H -->|TP receptor| M[Vasoconstriction, pro-thrombotic]
-
Trigger phase: Inflammatory stimuli (IL-1Ξ², TNF-Ξ±, mechanical damage, hypoxia) β activate phospholipase A2 (PLA2) β cleaves arachidonic acid from membrane phospholipids (especially phosphatidylcholine)
-
COX enzyme conversion:
- COX-1: Constitutively expressed, housekeeping functions
- Gastric mucosa: PGE2 and PGI2 β mucus secretion, bicarbonate production, mucosal blood flow
- Platelets: TXA2 β platelet aggregation
- Kidneys: PGE2 and PGI2 β renal blood flow, sodium excretion
- COX-2: Inducible (2-4 hours post-stimulus), upregulated by NF-ΞΊB and CREB
- Inflammation sites: high PGE2 production
- CNS: fever generation at circumventricular organs
- Also constitutive in kidney, brain, reproductive organs
-
Prostaglandin-specific synthases convert PGH2 to terminal products:
- mPGES-1 (microsomal PGE synthase-1): inducible, couples with COX-2 β PGE2
- H-PGDS (hematopoietic PGD synthase): immune cells β PGD2
- L-PGDS (lipocalin-type): CNS, male reproductive β PGD2
- PGIS (prostacyclin synthase): endothelium β PGI2
- TXAS (thromboxane synthase): platelets β TXA2
-
Receptor signaling (all GPCRs):
- EP1 (PGE2): Gq β CaΒ²βΊ β β smooth muscle contraction, pain sensitization
- EP2 (PGE2): Gs β cAMP β β vasodilation, immunosuppression (inhibits Th1, enhances IL-10)
- EP3 (PGE2): Gi β cAMP β β fever (hypothalamic action), gastric acid reduction
- EP4 (PGE2): Gs β cAMP β β bone formation, anti-inflammatory (suppresses TNF-Ξ±)
- IP (PGI2): Gs β cAMP β β vasodilation, anti-platelet, anti-atherogenic
- TP (TXA2): Gq β CaΒ²βΊ β β vasoconstriction, platelet aggregation
- FP (PGF2Ξ±): Gq β CaΒ²βΊ β β uterine contraction, luteolysis
- DP1 (PGD2): Gs β vasodilation, sleep promotion
- DP2/CRTH2 (PGD2): Gi β chemotaxis of Th2 cells, eosinophils (allergic inflammation)
-
Metabolic inactivation:
- 15-hydroxyprostaglandin dehydrogenase (15-PGDH) β rapid degradation (half-life: seconds to minutes)
- Ensures local, transient action
Early inflammation (0-24h):
- COX-2 β β PGE2 β β EP1/EP3 activation β sensitizes TRPV1 and P2X3 nociceptors β hyperalgesia
- Hypothalamic EP3 β raises thermostat set point β fever
- EP2/EP4 β vasodilation, vascular permeability β edema
Late inflammation / Resolution (24-72h):
- Same PGE2, different context
- EP2/EP4 on macrophages β suppress TNF-Ξ±, IL-1Ξ², IL-12 production
- EP2 β upregulates 15-LOX β class switch to Resolvins and Lipoxins
- EP4 β enhances efferocytosis (macrophage clearance of apoptotic neutrophils)
- This dual role explains why blocking PGE2 prevents both pain AND resolution
NSAID paradox and the resolution deficit: NSAIDs block COX non-selectively, eliminating pain/fever but also:
- Gastric ulceration (loss of PGE2/PGI2 mucosal protection β clinical threshold: >5 days NSAID use increases ulcer risk 4-fold)
- Delayed wound healing (PGE2 needed for Phase 3-4 tissue repair, collagen synthesis, angiogenesis)
- Impaired fracture healing (PGE2 drives osteoblast differentiation)
- Kidney dysfunction (PGE2/PGI2 maintain glomerular filtration during volume depletion)
- Resolution deficit: blocks PGE2-driven lipid mediator class switching to SPMs β inflammation persists longer despite symptom suppression
Metamodel connections:
- Selfish immune system: PGE2 dual role reflects immune system balancing self-protection (inflammation) with self-preservation (resolution)
- Evolutionary mismatch: Chronic NSAID use blocks ancient resolution pathways, creating persistent low-grade inflammation despite symptom control
- Allostatic load: Chronic PGE2 elevation (obesity, metabolic syndrome) drives insulin resistance via EP3 receptors on adipocytes
High relevance:
- Chronic pain patients on NSAIDs: monitor for gastric symptoms, delayed healing, cardiovascular risk (PGI2 suppression)
- IBD: COX-2-derived PGE2 is paradoxically protective in colitis β NSAIDs worsen disease
- Rheumatoid arthritis: PGE2 drives joint inflammation (COX-2 β in synovium), but also promotes resolution β selective COX-2 inhibitors reduce pain but delay repair
- Post-surgical: PGE2 essential for wound healing β NSAID timing matters (avoid first 48h for tissue repair)
- Fever in infection: PGE2-mediated fever is adaptive (enhances immune function) β routine suppression may prolong illness
Clinical thresholds:
- PGE2 in synovial fluid: >1000 pg/mL indicates active joint inflammation
- Urinary PGE2 metabolite (PGE-M): marker of systemic COX-2 activity, elevated in cancer (>1500 ng/mg creatinine)
- TXA2/PGI2 ratio (via metabolites): >2.0 indicates prothrombotic state (cardiovascular risk)
Selective vs non-selective COX inhibition:
- Aspirin (irreversible COX-1/COX-2): 75-100 mg/day for cardiovascular protection (suppresses TXA2, spares PGI2 via endothelial COX-2)
- Selective COX-2 inhibitors (celecoxib): reduce gastric risk but increase cardiovascular events (suppress PGI2, spare platelet TXA2)
Supporting resolution:
- Omega-3 fatty acids (EPA/DHA): substrate competition β reduces arachidonic acid availability, shifts to Resolvins
- Target: omega-6/omega-3 ratio <4:1
- Timing NSAIDs around resolution: avoid during tissue repair phases (post-exercise, post-injury days 2-7)
Natural COX-2 modulation (without complete blockade):
- Curcumin: selective COX-2 inhibition via NF-ΞΊB suppression, but allows basal PGE2 production
- Ginger: inhibits both COX and LOX, shifts toward anti-inflammatory prostaglandins
- Omega-3 fatty acids: competitive COX substrate, reduces PGE2 magnitude without eliminating it
- Prostaglandin family includes PGE2, PGD2, PGF2Ξ±, PGI2 (prostacyclin), TXA2 (thromboxane) β all derived from 20-carbon arachidonic acid
- COX-1 is constitutive (housekeeping): gastric protection, platelet function, renal regulation
- COX-2 is inducible (2-4h post-stimulus): inflammation, fever, tissue repair β also constitutive in kidney/brain
- PGE2 has four receptors (EP1-4) creating context-dependent pro- and anti-inflammatory effects
- EP2/EP4 activation on macrophages β suppresses TNF-Ξ±, IL-12, upregulates IL-10 (anti-inflammatory)
- EP2 drives lipid mediator class switching: upregulates 15-LOX β production of Resolvins, Lipoxins, Protectins
- PGI2 (prostacyclin) is vasodilatory, anti-thrombotic (endothelial protection)
- TXA2 (thromboxane) is vasoconstrictive, pro-thrombotic (platelet aggregation)
- Half-life: seconds to minutes β rapid inactivation by 15-PGDH ensures localized action
- Aspirin irreversibly acetylates COX-1/COX-2 β lasts lifetime of platelet (7-10 days) β low-dose cardioprotection
- NSAIDs increase ulcer risk 4-fold after 5 days, impair fracture healing by 30-50%, delay wound closure by 24-48h
- PGE2 >1000 pg/mL in synovial fluid = active joint inflammation
- Chronic NSAID use blocks PGE2-driven resolution, creating resolution deficit despite symptom control
- PGE2 β most studied subtype, dual pro- and anti-inflammatory roles
- Arachidonic acid β substrate for all prostaglandins, released by Phospholipase A2
- COX-1 β constitutive enzyme, housekeeping prostaglandin production
- COX-2 β inducible enzyme, inflammation-driven prostaglandin synthesis
- Eicosanoids β prostaglandins are subclass, alongside Leukotrienes and Lipoxins
- NSAIDs β non-selective COX inhibitors, block all prostaglandin synthesis
- Aspirin β irreversible COX acetylation, cardioprotective at low dose via TXA2 suppression
- Inflammation β prostaglandins mediate vascular phase, pain sensitization, fever, but also drive resolution
- Pain β PGE2 sensitizes TRPV1 and P2X3 nociceptors via EP1/EP3
- Fever β PGE2 acts on hypothalamic EP3 receptors, raises thermostat set point
- Resolution β PGE2 via EP2/EP4 triggers lipid mediator class switching to SPMs
- Wound healing β PGE2 essential for fibroblast proliferation, collagen synthesis, angiogenesis
- Lipid mediator class switching β PGE2 EP2 upregulates 15-LOX, shifts to resolvin production
- Omega-3 fatty acids β competitive COX substrate, reduces arachidonic acid-derived prostaglandin magnitude
- NF-ΞΊB β transcription factor that upregulates COX-2 expression in inflammation
- IL-10 β anti-inflammatory cytokine enhanced by PGE2 EP2/EP4 signaling
- TNF-Ξ± β pro-inflammatory cytokine suppressed by PGE2 EP2/EP4 in resolution phase
- Gastric ulcers β NSAIDs suppress protective PGE2/PGI2 in gastric mucosa
- Chronic pain β chronic PGE2 sensitization of nociceptors, but resolution requires PGE2-driven class switch
- Platelets β TXA2 from COX-1 drives aggregation, opposed by endothelial PGI2
- Endothelium β produces PGI2 via COX-2 for vasodilation and anti-thrombotic protection
- Hypothalamus β PGE2 crosses blood-brain barrier at circumventricular organs, drives fever via EP3
- IBD β paradoxically, COX-2-derived PGE2 is protective in colitis, NSAIDs worsen disease
- Efferocytosis β PGE2 EP4 enhances macrophage clearance of apoptotic cells during resolution
- Module 4: Prostaglandins in inflammatory cascade, dual role in immune regulation
- Module 5: Lipid mediators, resolution pharmacology, NSAID effects on metabolism and healing